Vaughn M. Kailian is Director & 10% at Pacira Pharmaceuticals, Inc. (PCRX). They have made 6 open-market trades across 4 companies since 2007, most recently 2014-03-10.
CIK 0001180429
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.0M since 2012, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PETX | SELL | 2014-03-10 | 2014-03-12 | $20.02 | $12.0M | -45.1% | -7.4% | -7.4% |
| PCRX | SELL | 2013-03-11 | 2013-03-13 | $27.86 | $13.9M | -18.1% | +0.8% | +0.8% |
| PCRX | BUY | 2012-02-08 | 2011-02-10 | $— | — | -18.1% | +0.8% | +0.8% |
| VSTM | BUY | 2012-02-01 | 2012-02-03 | $10.00 | $1.0M | -27.9% | -2.7% | -2.7% |
| MEMY | SELL | 2007-09-14 | 2007-09-18 | $2.10 | $58K | N/A | N/A | N/A |
| MEMY | SELL | 2007-09-12 | 2007-09-14 | $2.13 | $153K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.